Search
forResearch 10 of 1000+
- A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
- Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- FDA declines approval of testosterone drug for third time
- Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
- 18F-FDG PET Uptake in the Scalp After Platelet-Rich Plasma Therapy
- FDA Approved pediatric antihypertensive agents
Community 10 of 76
- Finasteride alternative close to fda approval in the US
- Peeps who arent able to get gains even after using fda approved meds
- Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
- FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
- Just FYI, Here are pictures of 6 months results on Clascoterone 5%. Is it remarkable? No. But it seems likely to be FDA approved considering 1% is already available. This is a win, especially if you pair it with other treatments like Finasteride.
- New warning by FDA on topical finasteride
- Dutasteride would have been approved for AGA by the US FDA.
- There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
- Good news for stem cells hair therapies - US federal judge: using patients' stem cells does NOT fall under FDA jurisdiction
- US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
Learn
— no results
Try a deeper search in learn →